🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Metrnomic adjuvant after definitive CTRT in HNSCC is it usefull? Read our phase 3 study for the answer. Vanita Noronha, MBBS MD DM Pan Pantziarka Nandini Menon Head and Neck Cancer International Group Ezra Cohen Robert Haddad Prof. Anil D'Cruz Prathamesh Pai Venky ashayoncology sciencedirect.com/science/articl…

Long term outcomes of phase I/II study of palliative triple metronomic... sciencedirect.com/science/articl… Dr (Prof). Vijay Patil

Impressive discussion on Inequities in Access to Standards of Cancer Care, using India as an case example by Dr Minit Jalan Shah. - did you know that Tata Memorial Hospital was built in record time 10 months!!! #esmoasia23

So proud of the junior most member of our team at Tata Memorial Hospital- Dr Minit Shah. Thanks Evelyn Wong for highlighting this. Nandini Menon Dr (Prof). Vijay Patil Ajaykumar Singh TMH Medical Oncology Alumni Kunal Jobanputra MD, DM

Parween et al. present a pan-cancer analysis of homologous recombination DNA repair pathway genes in the Indian population. Read here: bit.ly/3GXbtvh #CancerResearch #CRST #Oncology #DNA #MedTwitter

A much awaited answer from our Solid Tumour Unit 2 group at Tata Memorial Center. Congratulations Dr Vanita, Dr Vijay, Dr Kumar sir and the entire Solid Tumour Unit 2 team!!!! ejcancer.com/article/S0959-…

Neoadjuvant chemotherapy in locally advanced Sinonasal Teratocarcinosa... sciencedirect.com/science/articl… Dr (Prof). Vijay Patil Vanita Noronha, MBBS MD DM Minit Shah

Gef vs Gef plus Pemetrexed & Carboplatin Chemotherapy in EGFR-Variant Lung Cancer—Long-Term Results of a Randomized Clinical Trial A paper very close to our hearts, true reflection of the hard work of our solid unit 2 department. jamanetwork.com/journals/jamao… jamanetwork.com/journals/jamao…

Indian real-world data (JCO Global Oncology) confirms trastuzumab before/after surgery + maintenance enhances survival in HER2-positive breast cancer, esp when pCR achieved. Need early dx & universal access to HER2 drugs in LMICs. doi.org/10.1200/GO-24-… #GlobalOnc

Big congrats to Dr. Sudeep Gupta & TMH Breast DMG team! New JCO Global Oncology study of 1,004 HER2+ BC patients on NAT. ✅ pCR: 22.5% → OS 87.3% vs 64.7% (no pCR) 💉 Trastuzumab >24w = best OS (80.5%) ⚠️ Baseline tumor burden prognostic even after pCR Access + duration

Lower-dose abiraterone demonstrated comparable efficacy to standard-dose abiraterone, positioning itself as a viable alternative for patients with mCRPC, according to data presented at #ASCO25. | Minit Shah urologytimes.com/view/lower-dos…